Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAC NASDAQ:CLDX NASDAQ:INVA NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANACArctos NorthStar Acquisition$10.19$9.75$9.44▼$10.20$402.81MN/A53,611 shs705 shsCLDXCelldex Therapeutics$22.08-1.3%$22.29$14.40▼$47.00$1.49B1.221.47 million shs1.33 million shsINVAInnoviva$20.43+2.0%$19.55$16.67▼$22.00$1.26B0.38816,083 shs650,802 shsNVAXNovavax$7.47-1.5%$7.40$5.01▼$15.22$1.21B2.59.39 million shs6.39 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANACArctos NorthStar Acquisition0.00%0.00%0.00%0.00%0.00%CLDXCelldex Therapeutics-1.34%-1.69%-3.20%+13.29%-42.60%INVAInnoviva+2.00%+1.34%+10.85%+4.02%+6.57%NVAXNovavax-1.45%-4.72%+9.05%+1.08%-32.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANACArctos NorthStar AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACLDXCelldex Therapeutics1.8015 of 5 stars3.43.00.00.02.80.00.0INVAInnoviva4.7199 of 5 stars3.51.00.04.24.01.73.1NVAXNovavax4.4253 of 5 stars3.12.00.04.72.10.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANACArctos NorthStar Acquisition 0.00N/AN/AN/ACLDXCelldex Therapeutics 2.78Moderate Buy$46.67111.35% UpsideINVAInnoviva 3.00Buy$42.75109.25% UpsideNVAXNovavax 2.13Hold$14.2991.24% UpsideCurrent Analyst Ratings BreakdownLatest ANAC, CLDX, INVA, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025NVAXNovavaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.008/20/2025CLDXCelldex TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$44.00 ➝ $38.008/20/2025CLDXCelldex TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$56.00 ➝ $48.008/20/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $62.008/20/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $42.008/20/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$9.00 ➝ $7.008/11/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.008/11/2025INVAInnovivaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$45.007/22/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANACArctos NorthStar AcquisitionN/AN/A$0.18 per share56.23($0.63) per shareN/ACLDXCelldex Therapeutics$7.02M208.88N/AN/A$9.87 per share2.24INVAInnoviva$358.71M3.59$3.49 per share5.85$11.34 per share1.80NVAXNovavax$1.08B1.12N/AN/A$0.23 per share32.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANACArctos NorthStar Acquisition$7.16MN/A0.00∞N/AN/A-70.78%3.97%N/ACLDXCelldex Therapeutics-$157.86M-$3.01N/AN/AN/A-3,446.88%-27.61%-26.20%11/5/2025 (Estimated)INVAInnoviva$23.39M$0.3165.9113.18N/A10.44%18.67%9.92%11/5/2025 (Estimated)NVAXNovavax-$187.50M$2.283.2893.380.1039.20%-142.33%28.65%11/11/2025 (Estimated)Latest ANAC, CLDX, INVA, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CLDXCelldex Therapeutics-$0.86-$0.85+$0.01-$0.85$1.13 million$0.73 million8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 million8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANACArctos NorthStar AcquisitionN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANACArctos NorthStar AcquisitionN/A0.150.15CLDXCelldex TherapeuticsN/A19.6719.67INVAInnoviva0.362.642.44NVAXNovavax5.932.362.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANACArctos NorthStar Acquisition71.06%CLDXCelldex TherapeuticsN/AINVAInnoviva99.12%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipANACArctos NorthStar AcquisitionN/ACLDXCelldex Therapeutics4.40%INVAInnoviva2.25%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANACArctos NorthStar AcquisitionN/A39.53 millionN/ANot OptionableCLDXCelldex Therapeutics15066.41 million63.49 millionOptionableINVAInnoviva10063.02 million61.60 millionOptionableNVAXNovavax1,990162.42 million160.80 millionOptionableANAC, CLDX, INVA, and NVAX HeadlinesRecent News About These CompaniesHC Wainwright Reaffirms "Buy" Rating for Novavax (NASDAQ:NVAX)August 30 at 8:20 AM | marketbeat.comKohl’s, Bill.com, Novavax, Jazz, Nvidia: Trending by AnalystsAugust 30 at 5:10 AM | tipranks.comHC Wainwright Initiates Coverage on Novavax (NASDAQ:NVAX)August 30 at 2:23 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for Novavax Q3 Earnings?August 30 at 2:43 AM | americanbankingnews.comNovavax, Inc. (NVAX) Wins FDA Approval for Nuvaxovid BLAAugust 29 at 12:14 PM | finance.yahoo.comRobert Kennedy Jr. Announces End Of FDA Covid Mandates – Clears Moderna, Pfizer, Novavax For High-Risk GroupsAugust 28 at 3:09 PM | msn.comNovavax (NVAX) Is Up After FDA Approves Updated Nuvaxovid for Key High-Risk Groups—What's ChangedAugust 28 at 3:09 PM | finance.yahoo.comFDA Approves Updated COVID-19 Vaccines but With RestrictionsAugust 28 at 1:06 PM | zacks.comWhy Novavax (NVAX) is a Top Momentum Stock for the Long-TermAugust 28 at 10:50 AM | zacks.comNovavax, Inc. (NVAX) Launches Protein-Based Vaccine for High-Risk AdultsAugust 28 at 6:31 AM | insidermonkey.com511,742 Shares in Novavax, Inc. $NVAX Purchased by Jump Financial LLCAugust 28 at 6:15 AM | marketbeat.comRFK Jr. Rescinds Emergency Authorizations For COVID-19 VaccinesAugust 27 at 3:30 PM | benzinga.comNovavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.August 27 at 3:07 PM | prnewswire.comNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItAugust 27 at 10:00 AM | zacks.comNovavax, Inc. $NVAX Shares Sold by Vanguard Group Inc.August 25, 2025 | marketbeat.comNovavax (NVAX): How Debt Extension and Fresh Funding Shape Its Current ValuationAugust 24, 2025 | finance.yahoo.comNotable healthcare headlines for the week: Novo Nordisk, Medtronic, Novavax in focusAugust 24, 2025 | seekingalpha.comNovavax Faces Stock Slump Amid DowngradeAugust 23, 2025 | tipranks.comNovavax Shares Are Trading Higher Thursday: What's Going On?August 22, 2025 | benzinga.comWhat the Options Market Tells Us About NovavaxAugust 22, 2025 | benzinga.comBank of America Reiterates Underperform Rating for Novavax (NASDAQ:NVAX)August 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANAC, CLDX, INVA, and NVAX Company DescriptionsArctos NorthStar Acquisition NASDAQ:ANACArctos NorthStar Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It focuses on sports, media, and entertainment sectors. The company was founded in 2020 and is based in Dallas, Texas.Celldex Therapeutics NASDAQ:CLDX$22.08 -0.30 (-1.34%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$22.08 0.00 (0.00%) As of 08/29/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Innoviva NASDAQ:INVA$20.43 +0.40 (+2.00%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$20.42 0.00 (-0.02%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Novavax NASDAQ:NVAX$7.47 -0.11 (-1.45%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.48 +0.01 (+0.13%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
